Vaxinano Highlights Zoo Partnership and Efficacy Data for Nasal Toxoplasmosis Vaccine

According to a recent LinkedIn post from Vaxinano, the company’s teams worked with Belgian zoo Pairi Daiza on a vaccination campaign against lethal toxoplasmosis in several primate species, including critically endangered animals. The post indicates that around 15 Saimiri boliviensis were immunized using Vaxinano’s VXN-TOXO nasal-spray vaccine, described as adjuvant-free and innovative.

The LinkedIn post references 2025 data published in the journal Vaccines that reportedly show no adverse events and a 96.7% reduction in toxoplasmosis-related mortality across 20 zoological institutions. If these results are replicated and broadly recognized, they could strengthen VXN-TOXO’s positioning in the animal health and conservation niche, potentially supporting commercial adoption in zoos and wildlife centers.

By highlighting Pairi Daiza’s role as a major European zoological park and its focus on conservation and biodiversity, the post frames the collaboration within the “One Health” paradigm linking human, animal, and environmental health. For investors, the emphasis on One Health and high-profile conservation partners may signal Vaxinano’s strategy to build credibility in specialized veterinary markets, which could serve as a platform for future product extensions or regulatory pathways.